IL135705A0 - Using polyamide nuceic acid oligomers to engender a biological response - Google Patents

Using polyamide nuceic acid oligomers to engender a biological response

Info

Publication number
IL135705A0
IL135705A0 IL13570598A IL13570598A IL135705A0 IL 135705 A0 IL135705 A0 IL 135705A0 IL 13570598 A IL13570598 A IL 13570598A IL 13570598 A IL13570598 A IL 13570598A IL 135705 A0 IL135705 A0 IL 135705A0
Authority
IL
Israel
Prior art keywords
pna oligomers
materials
engender
biological response
oligomers
Prior art date
Application number
IL13570598A
Other languages
English (en)
Original Assignee
Mayo Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/953,269 external-priority patent/US6472209B1/en
Priority claimed from US09/168,791 external-priority patent/US6723560B2/en
Application filed by Mayo Foundation filed Critical Mayo Foundation
Publication of IL135705A0 publication Critical patent/IL135705A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
    • C07K14/003—Peptide-nucleic acids (PNAs)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2123/00—Preparations for testing in vivo
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/318—Chemical structure of the backbone where the PO2 is completely replaced, e.g. MMI or formacetal
    • C12N2310/3181—Peptide nucleic acid, PNA

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Psychiatry (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Polyamides (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Materials For Medical Uses (AREA)
IL13570598A 1997-10-17 1998-10-16 Using polyamide nuceic acid oligomers to engender a biological response IL135705A0 (en)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US08/953,269 US6472209B1 (en) 1997-10-17 1997-10-17 Using polyamide nucleic acid oligomers to engender a biological response
US09/016,685 US6743627B1 (en) 1997-10-17 1998-01-30 Using polyamide nucleic acid oligomers to engender a biological response
US16851998A 1998-10-08 1998-10-08
US09/168,791 US6723560B2 (en) 1998-10-08 1998-10-08 Using polyamide nucleic acid oligomers to engender a biological response
US09/168,714 US6989270B1 (en) 1997-10-17 1998-10-08 Using polyamide nucleic acid oligomers to engender a biological response
PCT/US1998/021888 WO1999020643A1 (fr) 1997-10-17 1998-10-16 Utilisation d'oligomeres d'acides nucleiques de polyamide pour declencher une reaction biologique

Publications (1)

Publication Number Publication Date
IL135705A0 true IL135705A0 (en) 2001-05-20

Family

ID=27533701

Family Applications (1)

Application Number Title Priority Date Filing Date
IL13570598A IL135705A0 (en) 1997-10-17 1998-10-16 Using polyamide nuceic acid oligomers to engender a biological response

Country Status (12)

Country Link
US (1) US6989270B1 (fr)
EP (1) EP1042349B1 (fr)
JP (1) JP2003523307A (fr)
AT (1) ATE405575T1 (fr)
AU (1) AU741246B2 (fr)
BR (1) BR9814866A (fr)
CA (1) CA2306731A1 (fr)
DE (1) DE69839921D1 (fr)
DK (1) DK1042349T3 (fr)
ES (1) ES2312192T3 (fr)
IL (1) IL135705A0 (fr)
WO (1) WO1999020643A1 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6723560B2 (en) * 1998-10-08 2004-04-20 Mayo Foundation For Medical Education And Research Using polyamide nucleic acid oligomers to engender a biological response
US6472209B1 (en) 1997-10-17 2002-10-29 Mayo Foundation For Medical Education And Research Using polyamide nucleic acid oligomers to engender a biological response
US6989270B1 (en) 1997-10-17 2006-01-24 Mayo Foundation For Medical Education And Research Using polyamide nucleic acid oligomers to engender a biological response
US6806363B1 (en) 1999-04-16 2004-10-19 Mayo Foundation For Medical Education & Research Cobalamin conjugates useful as antitumor agents
TWI228512B (en) 2000-10-25 2005-03-01 Mayo Foundation Transcobalamin binding conjugates useful for treating abnormal cellular proliferation

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1986005519A1 (fr) 1985-03-15 1986-09-25 James Summerton Reactif et procede d'analyse de polynucleotides
US5217866A (en) 1985-03-15 1993-06-08 Anti-Gene Development Group Polynucleotide assay reagent and method
US5470974A (en) 1985-03-15 1995-11-28 Neu-Gene Development Group Uncharged polynucleotide-binding polymers
US5783682A (en) 1990-07-27 1998-07-21 Isis Pharmaceuticals, Inc. Oligonucleotide mimics having nitrogen-containing linkages
US5719262A (en) 1993-11-22 1998-02-17 Buchardt, Deceased; Ole Peptide nucleic acids having amino acid side chains
DK51092D0 (da) 1991-05-24 1992-04-15 Ole Buchardt Oligonucleotid-analoge betegnet pna, monomere synthoner og fremgangsmaade til fremstilling deraf samt anvendelser deraf
US5539082A (en) 1993-04-26 1996-07-23 Nielsen; Peter E. Peptide nucleic acids
US5641625A (en) 1992-05-22 1997-06-24 Isis Pharmaceuticals, Inc. Cleaving double-stranded DNA with peptide nucleic acids
WO1995004749A1 (fr) 1993-08-05 1995-02-16 Isis Pharmaceuticals, Inc. Oligomeres permettant de moduler la fonction metabolique
AU7523794A (en) 1993-08-09 1995-02-28 Isis Pharmaceuticals, Inc. Oligomers for modulating viral processes
US6156501A (en) 1993-10-26 2000-12-05 Affymetrix, Inc. Arrays of modified nucleic acid probes and methods of use
GB2284209A (en) 1993-11-25 1995-05-31 Ole Buchardt Nucleic acid analogue-induced transcription of RNA from a double-stranded DNA template
US5703067A (en) * 1995-05-08 1997-12-30 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
WO1996035705A1 (fr) 1995-05-10 1996-11-14 Isis Pharmaceuticals, Inc. Inhibition, au moyen d'une invasion de brins oligomeres, de l'activation par transcription induite par un facteur de transcription
US6015710A (en) 1996-04-09 2000-01-18 The University Of Texas System Modulation of mammalian telomerase by peptide nucleic acids
GB9608803D0 (en) 1996-04-27 1996-07-03 Univ Newcastle Mitochondrial dna defects
IL133087A0 (en) 1997-05-28 2001-03-19 Nielsen Peter E Conjugated peptide nucleic acids having enhanced cellular uptake
CA2298067A1 (fr) 1997-07-24 1999-02-04 Ulo Langel Conjugues de peptides transporteurs et analogues d'acides nucleiques ainsi que leur utilisation
US6300318B1 (en) 1997-09-16 2001-10-09 Peter E. Nielsen Antibacterial and antibiotic methods using peptide nucleic acids and pharmaceutical compositions therefor
AU9570898A (en) 1997-09-18 1999-04-05 Gene Therapy Systems, Inc. Chemical modification of dna using peptide nucleic acid conjugates
US6472209B1 (en) * 1997-10-17 2002-10-29 Mayo Foundation For Medical Education And Research Using polyamide nucleic acid oligomers to engender a biological response
US6989270B1 (en) 1997-10-17 2006-01-24 Mayo Foundation For Medical Education And Research Using polyamide nucleic acid oligomers to engender a biological response

Also Published As

Publication number Publication date
WO1999020643A9 (fr) 1999-08-05
CA2306731A1 (fr) 1999-04-29
JP2003523307A (ja) 2003-08-05
AU1094099A (en) 1999-05-10
EP1042349A1 (fr) 2000-10-11
WO1999020643A1 (fr) 1999-04-29
ATE405575T1 (de) 2008-09-15
EP1042349B1 (fr) 2008-08-20
US6989270B1 (en) 2006-01-24
EP1042349A4 (fr) 2004-07-28
AU741246B2 (en) 2001-11-29
DK1042349T3 (da) 2008-11-10
ES2312192T3 (es) 2009-02-16
BR9814866A (pt) 2001-11-20
DE69839921D1 (de) 2008-10-02

Similar Documents

Publication Publication Date Title
DK0943097T3 (da) Fremgangsmåde til at påvise IgE
ATE319855T1 (de) Abspaltbare, nicht-flüchtige moleküle zur massenmarkierung
EP0701001A3 (fr) Méthode et système pour séparer, fractionner et analyser de l'ADN
WO2002093129A3 (fr) Methodes d'analyse des interactions entre proteines dans des cellules vivantes et entieres
BR9606907A (pt) Sistema de análise de solo e amostragem
WO2000012703A3 (fr) Molecules associees au transport de proteines
WO1997012039A3 (fr) Inositol-phosphatase contenant le site sh2
DK0871457T3 (da) Isolerede stromaceller og fremgangsmåder til anvendelse heraf
AU1855401A (en) Screening method for candidate drugs
ES2154736T3 (es) Metodo de analisis.
GB2291714B (en) Biological species detection method and biosensor therefor
NZ332641A (en) method of detecting a lysosomal storage disorder by assaying the level of an enzyme, protein or peptide associated with the disease
DE68909997D1 (de) Vorrichtung zur Kultur von tierischen Zellen, Kulturmethode und Mittel zum Nachweis der Kultur.
WO2001042503A3 (fr) Appareil et methodes de criblage de medicaments
DK1042349T3 (da) Anvendelse af polyamid-nukleinsyre-oligomerer til frembringelse af et biologisk respons
ATE319819T1 (de) Humane hirn-spezifische carboxypeptidase b
ATE306666T1 (de) Verfahren zur eiweissanalyse
ATE273389T1 (de) Rezeptor des y-y5 neuropeptids
MXPA02000293A (es) Isoformas de la amp ciclico fosfodiesterasa y metodos de uso.
HUP0100674A2 (hu) Mutáns prepo-neuropeptid-Y-t kódoló DNS-molekula, mutáns szignálpeptid és alkalmazásuk
DE69734890D1 (de) Rdgb-proteine
DE3887629D1 (de) Analyseverfahren und Vorrichtung zur Analyse von flüssigen Stoffen.
WO2003044170A3 (fr) Isoformes 4d7 phosphodiesterases d'adenosine 5' monophosphate cycliques et procedes d'utilisation correspondants
WO2001029256A3 (fr) Marqueurs de susceptibilite aux maux de tete
DK0820695T3 (da) Fremgangsmåde til forarbejdning af fjerkrægødning, stald til anvendelse dertil og gulv til denne